Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and...
Transcript of Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and...
![Page 1: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/1.jpg)
Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct Investigator, Kaiser Permanente Division of Research Clinical Assistant Professor, Stanford University School of Medicine (Affiliated)
![Page 2: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/2.jpg)
2 October 24, 2017
![Page 3: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/3.jpg)
3 October 24, 2017
Breast Cancer Subtypes
1. ER/PR+ – HER2+ – HER2-
2. ER/PR- – HER2+ – HER2- (TNBC, Triple-negative breast cancer)
![Page 4: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/4.jpg)
4 October 24, 2017
Gene Mutations that Increase Breast Cancer Risk 1. BRCA1/2 2. PALB2 3. p53 4. CHEK2 5. DNA repair genes (RAD51, ATM, etc.) 6. PTEN 7. CDH1
![Page 5: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/5.jpg)
5 October 24, 2017
Innate Immunity
Molecular Biology of the Cell 4th Edition
![Page 6: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/6.jpg)
6 October 24, 2017
Adaptive Immunity
![Page 7: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/7.jpg)
7 October 24, 2017
To Kill or Not To Kill, That is a Question!
What is Cancer Immunotherapy?
![Page 8: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/8.jpg)
8 October 24, 2017
Major Immune Cells for Cancer Immunotherapy
B lymphocyte T lymphocyte Dendritic cells Natural killer cells
![Page 9: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/9.jpg)
9 October 24, 2017
B Lymphocyte that Produce Antibodies
WikiJournal of Medicine 1 (2).DOI:10.15347/wjm/2014.010. ISSN 2002-4436
![Page 10: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/10.jpg)
10 October 24, 2017
T Lymphocyte
T cells that kill – Helper T cells – Cytotoxic T cells – Memory T cells – Regulatory T cells
A normal T lymphocyte image using scanning electronic microscopy by NIAID
![Page 11: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/11.jpg)
11 October 24, 2017
Types of Cancer Immunotherapy
Monoclonal antibody: Rituxan (rituximab) for B cell lymphoma Cancer vaccines: HPV vaccines for cervical, vulvar and anal
cancer. Immune Checkpoint Inhibitor: ipilimumab, nivolumab,
pembrolizumab, atezolizumab, avelumab, durvalumab, etc… CAR-T: Chimeric Antigen Receptor-T cells Adoptive cell transfer: tumor infiltrating T cells, autologous
dendritic cells
![Page 12: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/12.jpg)
12 October 24, 2017
Immune Checkpoint Regulation
Cancer cells develop escape systems to evade immune detection and killing
Immunotherapy is a type of targeted immune activation
B7 Family Ligands
B7-1 (CD80)
B7-2 (CD86)
B7-H1 (PD-L1)
B7-DC (PD-L2)
B7-H2 (L-ICOS)
CD28 Family Receptors
CD28
CTLA-4
PD-1
ICOS
APC Activated
T Lymphocyte
![Page 13: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/13.jpg)
13 October 24, 2017
How do Immune Checkpoint Inhibitors Work?
Ribs A. et al. N Engl J Med 2012;366:2517.
Ipilimumab Nivolumab
![Page 14: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/14.jpg)
14 October 24, 2017
Chimeric Antigen Receptor T Cells (CAR-T)
Co-stimulatory domain
Anti-CD19 antibody idiotype CD19
![Page 15: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/15.jpg)
15 October 24, 2017
Adoptive T Lymphocyte Transfer
![Page 16: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/16.jpg)
16 October 24, 2017
Checkpoint Inhibitors Approved for: Melanoma Kidney cancer Non-small cell lung cancer Merkel cell carcinoma Hodgkin’s lymphoma Head and neck cancer Bladder cancer Gastric and esophageal cancer Hepatocellular carcinoma Any cancer with Mismatched Repair (MMR) Protein deficiency
![Page 17: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/17.jpg)
Common side effects of checkpoint inhibitors
Diarrhea Skin rash Pneumonitis Hypothyroidism Hemolysis Liver dysfunction
17 | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only. October 24, 2017
![Page 18: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/18.jpg)
Checkpoint Inhibitors for Breast Cancer
![Page 19: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/19.jpg)
19 October 24, 2017
Breast Cancer Subtypes
1. ER/PR+ – HER2+ – HER2-
2. ER/PR- – HER2+ – HER2- (TNBC, Triple-negative breast cancer)
![Page 20: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/20.jpg)
Clinical trials with checkpoint inhibitors
20 October 24, 2017
Trial Response
Keynote-12 8% all Triple negative
Keynote-86 5% all PD-L1 + Avelumab 5.4%, all but one PD-L1 + Atezolizumab 26% 1st line, 13% 2nd line Durvaluamb and Tremelizumab 3/18 responded, 3/7 TN, 0/11 ER+ Atezolizumab and Nab-Paclitaxel 67% 1st line, 27% 2nd line
![Page 21: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/21.jpg)
Durable response to checkpoint inhibitor
21 | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only. October 24, 2017
Nanda et al. Journal of Clinical Oncology 34, (2016) 2460-2467.
![Page 22: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/22.jpg)
22 October 24, 2017
I-SPY-2 Trial: Pembrolizumab plus Neoadjuvant Chemotherapy for Breast Cancer Tumor size: 2.0 by imaging or 2.5 cm by exam Taxol weekly plus Pembrolizumab for 12 weeks followed by AC x 4 cycles
Nanda et al. ASCO Annual meeting Chicago 2017
![Page 23: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/23.jpg)
NSABP-B59/GBGXX
Atezolizumab plus neoadjuvant chemotherapy TN-BC
23 | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only. October 24, 2017
![Page 24: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/24.jpg)
24 October 24, 2017
PD-L1 Expression in Breast Cancer
Adams et al. JCO 2014, 32, 2959.
![Page 25: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/25.jpg)
25 October 24, 2017
PD-L1 Expression and Prognosis in Metastatic Breast Cancer
Adams et al. JCO 2014, 32, 2959
![Page 26: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/26.jpg)
26 October 24, 2017
Priming Microenvironment for Checkpoint Inhibitor
Group 1: Radiation Gy x 3 Group 2: Doxorubicin 15mg/m2 x 2 weeks Group 3: Cyclophosphomide 50mg PO x 2 weeks Group 4: Cisplatin 40mg/m2 x 2 weeks Group 5: No treatment Nivolumab --50 patients --ORR 26%
Tonic Trial ESMO 2017
![Page 27: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/27.jpg)
Checkpoint Inhibitors for Ovarian Cancer
![Page 28: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/28.jpg)
28 October 24, 2017
Nivolumab for Ovarian Cancer
Hamanishi et al. JCO 2015
![Page 29: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/29.jpg)
JAVELIN Ovarian 100
Phase III First line platinum-based chemotherapy + Avelumab Stage III and IV
29 | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only. October 24, 2017
![Page 30: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/30.jpg)
30 October 24, 2017
Factors Predictive of Benefit from Checkpoint Inhibitor Tumor biology PD-L1 expression MMR deficiency Tumor infiltrating T lymphocyte Gut microbial composition Systemic factors
![Page 31: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/31.jpg)
31 October 24, 2017
Neutrophil Count Predictive of Progression in Melanoma Patients Treated with Pembrolizumab/Nivolumab
Neutrophils: Blue ≤3900 cells/µL; red 3901-5507 cells/µL; green ≥5501 cells/µL. P for difference <0.0001.
![Page 32: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/32.jpg)
32 October 24, 2017
Platelet Count Also Predictive of Progression
Platelets: Blue ≤215,000 cells/µL; red 216,000-303,000 cells/µL; green ≥304,000 cells/µL. P for difference <0.001.
![Page 33: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/33.jpg)
33 October 24, 2017
What is the Future of Immunotherapy?
Combination with chemotherapy Combination with targeted therapy Combination with different checkpoint inhibitor Identifying specific neoantigens for CAR-T Other novel approaches yet to be identified CRISPER gene editing
![Page 34: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/34.jpg)
34 October 24, 2017
Acknowledgements
Lisa Herrinton Mubarika Alavi Kaiser Permanente Cancer Program Our entire oncology team KP Public Affairs Office
![Page 35: Advances in Immunotherapy for Breast and Ovarian Cancer...Advances in Immunotherapy for Breast and Ovarian Cancer Minggui Pan, MD, PhD, Chief, Dept. of Oncology and Hematology Adjunct](https://reader033.fdocuments.in/reader033/viewer/2022042918/5f5f833e24ffb616b1531466/html5/thumbnails/35.jpg)
Questions?